Latest Stemline Therapeutics Inc. Stories
Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
NEW YORK, June 2, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc.
Stemline Therapeutics Receives Orphan Drug Designation for SL-401 for the Treatment of Acute Myeloid Leukemia
NEW YORK, March 9, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S.
Word of the Day
- A political dynamiter.